

## Skin Pathway Group – Dacarbazine in Advanced Malignant Melanoma

Indication:	Palliative therapy for unresectable Malignant Melanoma Stage III and Stage IV
Regimen details:	Dacarbazine 850mg/m <sup>2</sup> (*) IV Day 1  (*) Consider Dacarbazine 1000mg/m <sup>2</sup> for younger, fit patients
Administration:	Dacarbazine given as IV infusion in 500mls Sodium Chloride 0.9% over 1 hour, with an additional 500ml Sodium Chloride 0.9% run at the same time by piggyback, to reduce vein irritation.  Dacarbazine infusion rate can be decreased and volume can be increased to avoid venous pain during infusion. Dacarbazine is light-sensitive. It is likely that pain during the infusion may be caused by degradation products on exposure to light. Use light protective giving set or cover the line with aluminium foil, protect the infusion bag from light. Solution turns pink on exposure to light.
Frequency:	Every 21 days, up to 8 cycles
Pre-medication:	Not routinely given
Anti- emetics:	Very High emetogenicity Follow Local Anti-emetic Policy
Supportive medication:	Not routinely required
Extravasation:	Vesicant Dacarbazine should be administered with appropriate precautions to prevent extravasation

Version: 1.0 Supersedes: all other versions	Approved by LCA Skin Pathway Chemotherapy Lead: Mark Harries
Reason for Update: LCA Protocol Development	Approved by LCA Joint Delivery Subgroup Co-Chairs: Pauline McCalla & Rebecca Johl
Prepared by: Ravi Shaunak	Approved by LCA Medicines & Chemotherapy Steering Group Chair:
Second check by: Sanna Eestila	Date prepared: January 2015 Review Date: January 2017
<p>Disclaimer: The Joint Delivery Chemotherapy Nurse/Oncology Pharmacist Group is a sub-group of the Medicines &amp; Chemotherapy Steering Group (MCSG) working within the London Cancer Alliance Integrated Cancer System (LCA). The output of the LCA MCSG includes documentation that can be adopted by healthcare organisations at their discretion. It is the responsibility of each individual organisation to ensure that appropriate governance and safety clearance procedures within their own clinical service have been followed prior to implementation of any such pieces of work. LCA assume no responsibility for this process within individual organisations, and no responsibility for the clinical management of individual patients or patient groups. Any clinical queries regarding individual patients or documentation should be directed to the relevant clinical team within the most appropriate healthcare organisation.</p> <p>©LCA Copyright 2014</p>	

If there is any possibility that extravasation has occurred, contact a senior member of the medical team and follow local protocol for dealing with cytotoxic extravasation

Regular investigations: Prior to Cycle 1:  
 FBC Day 1 (within 14 days)  
 LFTs Day 1 (within 14 days)  
 U&Es Day 1 (within 14 days)

Prior to Day 1 (cycle 2 onwards):  
 FBC Day 1 (within 72 hours)  
 LFTs Day 1 (within 72 hours)  
 U&Es Day 1 (within 72 hours)  
 Re-staging Every 2-3 cycles

Toxicities: Anaemia, leucopenia, thrombocytopenia, nausea, vomiting, anorexia

**DOSE MODIFICATIONS**

**Haematological Toxicity**

Neutrophils (x 10 <sup>9</sup> /L)		Platelets (x 10 <sup>9</sup> /L)	Dose
≥ 1.5	&	≥ 100	100% dose
< 1.5	or	< 100	Delay for 1 week Repeat FBC, if recovered to above these levels give 100% dose. If not recovered to above these levels, continue to delay until recovered and reduced the next dose by 25%

**Non-haematological Toxicities**

**Renal Impairment**

Creatinine Clearance (ml/min)	Dacarbazine Dose
45 - 60	80%
30 - 45	75%
< 30	70%

**Hepatic Impairment**

Dacarbazine is activated and metabolised in the liver, therefore, can be hepatotoxic  
 Discuss with Consultant and consider dose reduction

Version: 1.0 Supersedes: all other versions	Approved by LCA Skin Pathway Chemotherapy Lead: Mark Harries
Reason for Update: LCA Protocol Development	Approved by LCA Joint Delivery Subgroup Co-Chairs: Pauline McCalla & Rebecca Johl
Prepared by: Ravi Shaunak	Approved by LCA Medicines & Chemotherapy Steering Group Chair:
Second check by: Sanna Eestila	Date prepared: January 2015 Review Date: January 2017
Disclaimer: The Joint Delivery Chemotherapy Nurse/Oncology Pharmacist Group is a sub-group of the Medicines & Chemotherapy Steering Group (MCSG) working within the London Cancer Alliance Integrated Cancer System (LCA). The output of the LCA MCSG includes documentation that can be adopted by healthcare organisations at their discretion. It is the responsibility of each individual organisation to ensure that appropriate governance and safety clearance procedures within their own clinical service have been followed prior to implementation of any such pieces of work. LCA assume no responsibility for this process within individual organisations, and no responsibility for the clinical management of individual patients or patient groups. Any clinical queries regarding individual patients or documentation should be directed to the relevant clinical team within the most appropriate healthcare organisation. ©LCA Copyright 2014	

Skin Pathway Group – Dacarbazine in Advanced Malignant Melanoma

Location of regimen delivery: Day case setting

Drug interactions: Hepatotoxic drugs and alcohol should be avoided during chemotherapy  
Dacarbazine is metabolised by cytochrome P450, therefore the co-administration of other drugs which are metabolised by the same hepatic enzymes can present a theoretical interaction  
Anti-epileptics: - reduced absorption of phenytoin

References: [www.medicines.org.uk](http://www.medicines.org.uk)  
Chapman PB et al. JCO (1999); 17 (9): 2745-2751  
Stockley's Drug Interactions. Interactions search: Dacarbazine: January 2009

Version: 1.0 Supersedes: all other versions	Approved by LCA Skin Pathway Chemotherapy Lead: Mark Harries
Reason for Update: LCA Protocol Development	Approved by LCA Joint Delivery Subgroup Co-Chairs: Pauline McCalla & Rebecca Johl
Prepared by: Ravi Shaunak	Approved by LCA Medicines & Chemotherapy Steering Group Chair:
Second check by: Sanna Eestila	Date prepared: January 2015      Review Date: January 2017
Disclaimer: The Joint Delivery Chemotherapy Nurse/Oncology Pharmacist Group is a sub-group of the Medicines & Chemotherapy Steering Group (MCSG) working within the London Cancer Alliance Integrated Cancer System (LCA). The output of the LCA MCSG includes documentation that can be adopted by healthcare organisations at their discretion. It is the responsibility of each individual organisation to ensure that appropriate governance and safety clearance procedures within their own clinical service have been followed prior to implementation of any such pieces of work. LCA assume no responsibility for this process within individual organisations, and no responsibility for the clinical management of individual patients or patient groups. Any clinical queries regarding individual patients or documentation should be directed to the relevant clinical team within the most appropriate healthcare organisation. ©LCA Copyright 2014	